April 2005 Inside this issue... New Division Heads at OCI New Director at PMH CSRC Visit us at... UHN's Research Internet Site

New Division Heads Appointed at OCI An overview of the new Research Divisions The first phase of OCI divisional restructuring has recently been completed, resulting in the creation of five new groupings and the appointment of a division head for each, as listed below. The second phase, currently underway, will see the re-organization of other important components of the OCI divisional structure. Watch for future announcements. Division of Applied Molecular Oncology Head: Dr. Fei-Fei Liu Members: Drs. Sylvia Asa, Robert Bristow, Susan Done, Brenda Gallie, David Hedley, Richard Hill, Suzanne Kamel-Reid, Richard Miller, Malcolm Moore, Jeremy Squire, Ian Tannock, Ming Tsao, Katherine Vallis Division of Biophysics and Bioimaging Head: Dr. Brian Wilson Members: Drs. Avi Chakrabartty, John Hunt, David Jaffray, James Lepock, Lothar Lilge, Michael Sherar, Jeffrey Siewerdsen, Alex Vitkin Division of Cancer Genomics and Proteomics Head: Dr. Linda Penn Members: Drs. Cheryl Arrowsmith, Sam Benchimol, Jean Gariépy, Lea Harrington, Emil Pai, Gil Privé, Christopher Richardson, David Rose, Aaron Schimmer, Elisabeth Tillier, Homayoun Vaziri Division of Signaling Biology Head: Dr. Mitsu Ikura Members: Drs. Peter Cheung, Razquallah Hakem, Igor Jurisica, Rama Khokha, Anne Koch, Armen Manoukian, Pam Ohashi, Vuk Stambolic, James Woodgett, Wen-Chen Yeh Division of Stem Cell and Developmental Biology Head: Dr. Rob Rottapel Members: Drs. Dwayne Barber, Norman Iscove, Tak Mak, Jeffrey Medin, Hans Messner, Mark Minden, Christopher Paige New Director Appointed at PMH CSRC In March, 2005, Dr. Padraig Warde assumed the Directorship of the PMH Clinical Studies Resource Centre. Having been at PMH since 1982, and having served as Chair of the University of Toronto Ethics Committee and as PMH's National Cancer Institute of Canada Clinical Trials Group representative, Dr. Warde has extensive experience in the administrative aspects of clinical research. Dr. Warde's primary research interests lie in prostate and testis cancer, and in his new role, he will drive innovation and infrastructure development in oncology clinical research. Research News This month the Research strategic planning process marked an important milestone with the release of the final set of recommendations from the Platform Task Force teams. For more information, see the Research Intranet.

Feedback/To Unsubscribe Net Results EXPRESS is brought to you by UHN Research Communications. We hope you have enjoyed receiving this message. If you have any feedback, or if you wish to unsubscribe, please email sazzam@uhnres.utoronto.ca. Images adapted from image archives of UHN Photographics and RSS.